+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Human African trypanosomiasis-neurological aspects



Human African trypanosomiasis-neurological aspects



Journal of Neurology 253(4): 411-416



Human African Trypanosomiasis (HAT),which is also known as sleeping sickness, is a major cause of death and disability in 36 countries in sub-Saharan Africa. The disease is caused by the protozoan parasite of the Trypanosoma genus which is transmitted by the bite of the tsetse fly. The two types of HAT, the East African form due to Trypanosoma b.rhodesiensei (T. b.rhodesiensi) and the West African form due to T. b.gambiense, differ in their tempo of infection but in both cases the disease is always fatal if untreated. As well as multiple systemic features seen in the early (haemolymphatic) stage of disease, the late (encephalitic stage) stage, is associated with a wide range of neurological features including neuropsychiatric, motor and sensory abnormalities. Accurate staging of the disease is absolutely essential because of the potentially fatal complications of melarsoprol treatment of late-stage disease, the most important of which is a severe post-treatment reactive encephalopathy (PTRE) the pathogenesis of which is not fully understood. However, there is not a universal consensus as to how late-stage disease should be diagnosed using CSF criteria, and this has been very problematic in HAT. A more recent alternative drug for late stage gambiense disease is eflornithine (DFMO). There is a pressing need for a non-toxic oral drug for both early and late stage disease that would obviate many of the problems of staging, and various possible strategies to achieve this goal are currently underway. However, control of the disease will also require more effective measures of reducing man/fly contact and also the allocation of much greater financial and infrastructural resources than are currently available in Africa.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049250702

Download citation: RISBibTeXText

PMID: 16541214

DOI: 10.1007/s00415-006-0093-3


Related references

Various neurological aspects of African trypanosomiasis. Annales de la Societe Belge de Medecine Tropicale 36(5 Bis): 645-654, 1956

Deceptive neurological forms of african human trypanosomiasis concerning 1 case abstract. Semaine Des Hopitaux De Paris: 2970, 1968

Neurological and neuropathological aspects of human trypanosomiasis. Annales de la Societe Belge de Medecine Tropicale 37(3): 379-426, 1957

Criteria for diagnosis of the neurological stage of human African trypanosomiasis: update and perspectives. Medecine Tropicale 68(1): 17-23, 2008

Clinical neurological signs of human African trypanosomiasis at the meningoencephalitis stage (apropos of 23 cases). Bulletin de la Societe de Pathologie Exotique et de Ses Filiales 81(3 Pt 2): 449-458, 1988

Radial immunodiffusion as a diagnostic test for African human trypanosomiasis in cases with neurological involvement. Seventeenth Meeting of the International Scientific Council for Trypanosomiasis Research and Control, Arusha, Tanzania, 19-24 October 1981: 101-106, 1983

Human African trypanosomiasis with serious intracranial hypertension Meeting of the French Neurological Society, July, 1963. Rev Neurol 109(1): 76-82, 1963

Clinical neurological signs of African Human Trypanosomiasis in the meningo-encephalitic period. Review of 23 cases. Bulletin de la Societe de Pathologie Exotique et de ses Filiales 81(3 bis): 449-458, 1988

Pathology of human African trypanosomiasis with reference to experimental African trypanosomiasis and infections of the central nervous system. British Medical Bulletin 41(2): 169-174, 1985

Clinical and Neuropathogenetic Aspects of Human African Trypanosomiasis. Frontiers in Immunology 10: 39, 2019

Pathological aspects of human African trypanosomiasis (HAT) in Uganda. Virchows Archiv 373(3): 249-265, 1977

Possible role of humoral factors (cryoglobulins) in the pathogenesis of various neurological manifestations of human African trypanosomiasis, with special reference to peripheral involvement. Bulletin de la Societe de Pathologie Exotique et de Ses Filiales 51(2): 177-180, 1958

Epidemiological aspects of human African trypanosomiasis in south Chad. Medecine Tropicale 49(4): 395-400, 1989

Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Tropica 97(1): 55-64, 2006

The elimination of human African trypanosomiasis is in sight: Report from the third WHO stakeholders meeting on elimination of gambiense human African trypanosomiasis. Plos Neglected Tropical Diseases 12(12): E0006925, 2018